1. Home
  2. SACH vs ELUT Comparison

SACH vs ELUT Comparison

Compare SACH & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

HOLD

Current Price

$1.21

Market Cap

46.9M

Sector

Real Estate

ML Signal

HOLD

ELUT

Elutia Inc.

HOLD

Current Price

$1.09

Market Cap

48.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SACH
ELUT
Founded
2010
2015
Country
United States
United States
Employees
27
N/A
Industry
Real Estate Investment Trusts
Medical Specialities
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.9M
48.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
SACH
ELUT
Price
$1.21
$1.09
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$2.00
$6.00
AVG Volume (30 Days)
441.1K
128.5K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
19.23%
N/A
EPS Growth
N/A
146.77
EPS
N/A
0.87
Revenue
N/A
$12,293,000.00
Revenue This Year
$145.00
N/A
Revenue Next Year
$6.80
$10.83
P/E Ratio
N/A
$1.26
Revenue Growth
N/A
N/A
52 Week Low
$0.90
$0.50
52 Week High
$1.45
$2.60

Technical Indicators

Market Signals
Indicator
SACH
ELUT
Relative Strength Index (RSI) 63.65 54.44
Support Level $0.99 $1.00
Resistance Level N/A $1.18
Average True Range (ATR) 0.07 0.08
MACD 0.02 0.01
Stochastic Oscillator 52.33 63.64

Price Performance

Historical Comparison
SACH
ELUT

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.

About ELUT Elutia Inc.

Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.

Share on Social Networks: